TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC). When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and a favorable safety profile across various preclinical animal models.

台湾台北，2024年3月18日（环球通讯社）--OBI Pharma，Inc.（TPEx:4174）今天宣布了OBI-992的临床前数据，OBI-992是一种潜在的同类最佳抗TROP2抗体药物偶联物（ADC）。当针对比较性TROP2 ADC进行评估时，OBI-992在各种临床前动物模型中表现出更高的抗肿瘤功效，优异的PK/PD特性以及良好的安全性。

Additionally, preclinical data will be presented on the novel site-specific proprietary GlycOBI™ ADC platform, demonstrating improved in vivo efficacy and stability in animal model studies. These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 5 to 10, 2024 in San Diego, California (USA).

此外，临床前数据将在新型位点特异性专有GlycOBI™ADC平台上呈现，证明在动物模型研究中改善了体内功效和稳定性。这些数据将于2024年4月5日至10日在美国加利福尼亚州圣地亚哥举行的美国癌症研究协会（AACR）年会上公布。

“Our data suggest OBI-992 has the potential to become a best-in-class TROP2 ADC. OBI-992 binds to a TROP2 epitope that is distinct from that of datopotamab and sacituzumab. OBI-992 shows lower non-specific binding, which should lead to decreased off-target cytotoxicity compared to benchmark ADCs. OBI-992 demonstrated remarkable anti-tumor efficacy in several CDX and PDX models.

“我们的数据表明，OBI-992有可能成为同类最佳的TROP2 ADC。OBI-992与TROP2表位结合，该表位不同于达托单抗和沙西妥珠单抗。OBI-992显示出较低的非特异性结合，与基准ADC相比，应导致脱靶细胞毒性降低。OBI-992在几种CDX和PDX模型中显示出显着的抗肿瘤功效。

In addition, OBI-992 showed excellent bystander effect and synergistic efficacy in combination with PARP inhibitors or anti-PD1 in animal models. OBI-992 was stable in circulation and well tolerated in cynomolgus monkeys, suggesting a good safety profile” said OBI’s Chief Scientific Officer, Ming-Tain Lai, Ph.D.

此外，OBI-992在动物模型中与PARP抑制剂或抗PD1组合显示出优异的旁观者效应和协同功效。OBI-992在循环中稳定，在食蟹猴中耐受性良好，表明其安全性良好”，OBI首席科学官Ming Tain Lai博士说。

“In addition, OBI developed a proprietary site-specific conjugation GlycOBI ADC platform to produce homogeneous ADCs. Preclinical studies demonstrated that the ADCs derived from GlycOBI platform showed better anti-tumor efficacy and PK profile. We are excited about the potential of applying this platform to generate novel ADCs to address unmet medical needs and pro.

“此外，OBI开发了一种专有的位点特异性缀合GlycOBI ADC平台，以产生均一的ADC。临床前研究表明，源自GlycOBI平台的ADC显示出更好的抗肿瘤功效和PK谱。我们对应用该平台产生新型ADC以解决未满足的医疗需求和pro的潜力感到兴奋。